Markets
Tendies
@tendies
Bought CTXR
Shares
up 1.88%
At 2.65, Exited 2.7
I believe CTXR could see significant movement due to its low float and promising drug pipeline, especially with Lymphir ready for market and strong re...
Read
More
Thesis
I believe CTXR could see significant movement due to its low float and promising drug pipeline, especially with Lymphir ready for market and strong results from Mino-Lok. This setup feels right for a swing trade given the circumstances around the company.
Go back
Flint.Trades
@flint.tr...
Bought CTXR
Shares
up 748%
At 0.39, Exited 3.32
Last add before going into tomorrow. Will look for an early market move and will possibly hold some into next week.
Thesis
Last add before going into tomorrow. Will look for an early market move and will possibly hold some into next week.
Go back
Flint.Trades
@flint.tr...
Bought CTXR
Shares
up 708%
At 0.41, Exited 3.32
Positioning myself for a breakout. Last play of the day for me.
Thesis
Positioning myself for a breakout. Last play of the day for me.
Go back
Flint.Trades
@flint.tr...
Bought CTXR
Shares
up 746%
At 0.39, Exited 3.32
Adding another decent amount here. Going to position myself for the potential break up. I like it a lot 🤝
Thesis
Adding another decent amount here. Going to position myself for the potential break up. I like it a lot 🤝
Go back
Flint.Trades
@flint.tr...
Bought CTXR
Shares
up 2695%
At 0.34, Exited 9.55
Adding more here. Looking a bit further on the higher timeframes could actually send us to 0.65 - 0.70. Could be a massive play.
Thesis
Adding more here. Looking a bit further on the higher timeframes could actually send us to 0.65 - 0.70. Could be a massive play.
Go back
Flint.Trades
@flint.tr...
Bought CTXR
Shares
up 2695%
At 0.34, Exited 9.55
Looking for a good bounce here.
Thesis
Looking for a good bounce here.
Go back
Tendies
@tendies
Bought CTXR
Shares
up 1104%
At 0.82, Exited 9.88
Citius Pharmaceuticals just received FDA approval for their new immunotherapy treatment, LYMPHIR. This approval could lead to significant revenue grow...
Read
More
Thesis
Citius Pharmaceuticals just received FDA approval for their new immunotherapy treatment, LYMPHIR. This approval could lead to significant revenue growth and investor interest, making it a strong long-term investment.
Go back
Tendies
@tendies
Bought CTXR
Shares
up 1104%
At 0.82, Exited 9.88
With the recent FDA approval for their immunotherapy treatment LYMPHIR, I believe CTXR has significant growth potential. This kind of approval can dri...
Read
More
Thesis
With the recent FDA approval for their immunotherapy treatment LYMPHIR, I believe CTXR has significant growth potential. This kind of approval can drive long-term value and solidify their presence in the pharmaceutical market.
Go back
